Note : Les descriptions sont présentées dans la langue officielle dans laquelle elles ont été soumises.
0
CA 03050221 2019-07-15
- 1 -
Description
Title of Invention: PHARMACEUTICAL COMPOSITION USED FOR
TREATMENT OF HTLV-1-ASSOCIATED MYELOPATHY
Technical Field
[0001]
The present invention relates to a pharmaceutical
composition for use in treating HTLV-1-associated
myelopathy.
Background Art
[0002]
HTLV-1-associated myelopathy (HAM), which is
developed in about 0.25% of the patients infected with
human T lymphotropic virus type 1 (HTLV-1), is an
intractable neurological disease having no established
therapy. The pathological condition of HAM is considered
as a nervous tissue disorder caused by excessive immune
response due to HTLV-1 infected cells. Steroid and IFNa,
which have been used for treatment up to present, have a
limited therapeutic effect and less effect on reduction
of infected cells, which are considered as a fundamental
cause for the disease. In addition to such serious
problem, the expression level of HTLV-1 gene is low,
unlike the AIDS virus gene, with the result that
CA 03050221 2019-07-15
- 2 -
therapeutic effects by a reverse transcriptase inhibitor
and a protease inhibitor were low.
[0003]
The number of patients who were afflicted with
inflammatory diseases associated with HTLV-1 is extremely
low. For the reason, elucidation of etiology and
development of therapeutic drugs for the diseases have
been rarely studied. Incidentally, it has been found
that a compound specified in Patent Literature 1 is
useful for treating, a kind of tumor, adult T-cell
leukemia lymphoma (ATL) (Patent Literature 2). However,
adult T-cell leukemia lymphoma (ATL) and HTLV-1-
associated myelopathy (HAM) are completely opposite in
onset mechanism; more specifically, ATL is a disease
developed under immunosuppressive condition; whereas HAM
is a disease producing inflammation by immunoenhancement.
Accordingly, the therapies and therapeutic agents for
them completely differ; more specifically, adult T-cell
leukemia lymphoma (ATL) is treated by an anti-cancer
agent; whereas, HTLV-1-associated myelopathy (HAM) is
treated by an anti-inflammatory agent. Besides, the
types of cells involved in pathological conditions of ATL
and HAM are completely different, as is apparent from the
document (Non Patent Literature 1).
Citation List
Patent Literatures
CA 03050221 2019-07-15
- 3 -
[0004]
Patent Literature 1: International Publication No. WO
2015/141616
Patent Literature 2: Japanese Patent No. 6009135
Non Patent Literature
[0005]
Non Patent Literature 1: Araya N., et al., Viruses, 3:
1532-1548, 2010
Summary of Invention
[0006]
The present invention provides a pharmaceutical
composition for use in treating HTLV-1-associated
myelopa thy.
[0007]
The present inventors revealed that a CD4*CD25+CCR4+
cell and other Ca4+ cells of a patient with HTLV-1-
associated myelopathy (HAM) overexpress EZH2. The
present inventors found that when autoproliferation
activity of PBMC derived from the spinal cord of a
patient with HAM is inhibited by an EZH2 inhibitor, IL-10
production ability is enhanced and the number of HTLV-1
infected cells reduces, with the result that apoptosis is
induced. The present inventors also found that the
effect of the EZH2 inhibitor is further enhanced in a
EZH1/2 dual inhibitor. From this, the present inventors
4
CA 03050221 2019-07-15
- 4 -
were aware that suppressing each of the enzyme activities
of EZH1 and EZH2 has a therapeutic significance for HAM.
The present invention was attained based on these
findings.
[0008]
More specifically, according to the present
invention, the following inventions are provided.
(1) A pharmaceutical composition comprising an
inhibitor selected from the group consisting of an EZH1
inhibitor, an EZH2 inhibitor and an EZH1/2 dual inhibitor
as an active ingredient, for use in treating HTLV-1-
associated myelopathy.
(2) The pharmaceutical composition according to (1),
wherein the inhibitor is an EZH1/2 dual inhibitor.
(3) The pharmaceutical composition according to (1),
wherein the inhibitor is a compound selected from
N-[(1,2-dihydro-4,6-dimethy1-2-oxo-3-
pyridinyl)methy1]-3-methy1-1-[(1S)-1-methylpropyl]-6-[6-
(1-piperaziny1)-3-pyridiny1]-1H-indole-4-carboxamide,
N-((4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-
yl)methyl)-5-(ethyl(tetrahydro-2H-piran-4-yl)amino)-4-
methy1-41-(morpholinomethyl)-[1,1'-biphenyl]-3-
carboxamide,
(2R)-7-bromo-2-[trans-4-(dimethylamino)cyclohexyl]-
N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-
2,4-dimethy1-1,3-benzodioxole-5-carboxamide, and
CA 03050221 2019-07-15
- 5 -
(2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-
N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-
2,4-dimethy1-1,3-benzodioxole-5-carboxamide,
or a pharmaceutically acceptable salt thereof.
(4) The pharmaceutical composition according to (1)
or (2), wherein the inhibitor is (2R)-7-bromo-2-[trans-4-
(dimethylamino)cyclohexyl]-N-[(4,6-dimethy1-2-oxo-1,2-
dihydropyridin-3-yl)methy1]-2,4-dimethy1-1,3-
benzodioxole-5-carboxamide, or (2R)-7-chloro-2-[trans-4-
(dimethylamino)cyclohexyl]-N-[(4,6-dimethy1-2-oxo-1,2-
dihydropyridin-3-yl)methy1]-2,4-dimethyl-1,3-
benzodioxole-5-carboxamide, or a pharmaceutically
acceptable salt thereof.
(5) The pharmaceutical composition according to (1)
or (2), wherein the inhibitor is (2R)-7-bromo-2-[trans-4-
(dimethylamino)cyclohexyl]-N-[(4,6-dimethy1-2-oxo-1,2-
dihydropyridin-3-yl)methy1]-2,4-dimethy1-1,3-
benzodioxole-5-carboxamide, or a pharmaceutically
acceptable salt thereof.
(6) The pharmaceutical composition according to (1)
or (2), wherein the inhibitor is (2R)-7-chloro-2-[trans-
4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethy1-2-oxo-1,2-
dihydropyridin-3-yl)methy1]-2,4-dimethy1-1,3-
benzodioxole-5-carboxamide, or a pharmaceutically
acceptable salt thereof.
(7) The pharmaceutical composition according to (1)
or (2), wherein the inhibitor is (2R)-7-chloro-2-[trans-
= = CA 03050221 2019-07-15
- 6 -
4-(dimethylamino)cyclohexyli-N-[(4,6-dimethy1-2-oxo-1,2-
dihydropyridin-3-yl)methy1]-2,4-dimethyl-1,3-
benzodioxole-5-carboxamide p-toluene sulfonate.
(8) A pharmaceutical composition for use in treating
HTLV-1-associated myelopathy, comprising a compound
selected from
N-[(1,2-dihydro-4,6-dimethy1-2-oxo-3-
pyridinyl)methy1]-3-methy1-1-[(1S)-1-methylpropy11-6-[6-
(1-piperaziny1)-3-pyridiny1]-1H-indole-4-carboxamide,
N-((4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-
yl)methyl)-5-(ethyl(tetrahydro-2H-piran-4-yl)amino)-4-
methy1-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-
carboxamide,
(2R)-7-bromo-2-Ltrans-4-(dimethylamino)cyclohexyll-
N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-
2,4-dimethy1-1,3-benzodioxole-5-carboxamide and
(2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-
N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-
2,4-dimethy1-1,3-benzodioxole-5-carboxamide,
or a pharmaceutically acceptable salt thereof.
(9) The pharmaceutical composition according to (8),
comprising (2R)-7-bromo-2-[trans-4-
(dimethylamino)cyclohexyl]-N-[(4,6-dimethy1-2-oxo-1,2-
dihydropyridin-3-yl)methy1]-2,4-dimethyl-1,3-
benzodioxole-5-carboxamide, or a pharmaceutically
acceptable salt thereof.
CA 03050221 2019-07-15
- 7 -
(10) The pharmaceutical composition according to (8),
comprising (2R)-7-chloro-2-[trans-4-
(dimethylamino)cyclohexyl]-N-[(4,6-dimethy1-2-oxo-1,2-
dihydropyridin-3-yl)methy1]-2,4-dimethyl-1,3-
benzodioxole-5-carboxamide, or a pharmaceutically
acceptable salt thereof.
(11) The pharmaceutical composition according to (8),
comprising (2R)-7-chloro-2-[trans-4-
(dimethylamino)cyclohexyll-N-[(4,6-dimethy1-2-oxo-1,2-
dihydropyridin-3-yl)methy1]-2,4-dimethyl-1,3-
benzodioxole-5-carboxamide p-toluene sulfonate.
(12) A method for treating HTLV-1-associated
myelopathy in a subject in need thereof, comprising
administering a therapeutically effective amount of an
inhibitor selected from the group consisting of an EZH1
inhibitor, an EZH2 inhibitor and an EZH1/2 dual inhibitor
to the patient.
(13) The method according to (12), wherein the
inhibitor is an EZH1/2 dual inhibitor.
(14) The method according to (12), wherein the
inhibitor is a compound selected from
N-[(1,2-dihydro-4,6-dimethy1-2-oxo-3-
pyridinyl)methyl]-3-methy1-1-[(1S)-1-methylpropy1]-6-[6-
(1-piperaziny1)-3-pyridiny1]-1H-indole-4-carboxamide,
N-((4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-
yl)methyl)-5-(ethyl(tetrahydro-2H-piran-4-yl)amino)-4-
CA 03050221 2019-07-15
_ 8 _
methy1-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-
carboxamide,
(2R)-7-bromo-2-[trans-4-(dimethylamino)cyclohexyl]-
N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-
2,4-dimethy1-1,3-benzodioxole-5-carboxamide, and
(2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-
N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-
2,4-dimethy1-1,3-benzodioxole-5-carboxamide,
or a pharmaceutically acceptable salt thereof.
(15) The method according to (12) or (13), wherein
the inhibitor is (2R)-7-bromo-2-[trans-4-
(dimethylamino)cyclohexyl]-N-[(4,6-dimethy1-2-oxo-1,2-
dihydropyridin-3-yl)methy1]-2,4-dimethy1-1,3-
benzodioxole-5-carboxamide, or (2R)-7-chloro-2-[trans-4-
(dimethylamino)cyclohexyl]-N-[(4,6-dimethy1-2-oxo-1,2-
dihydropyridin-3-yl)methy1]-2,4-dimethyl-1,3-
benzodioxole-5-carboxamide, or a pharmaceutically
acceptable salt thereof.
(16) The method according to (12) or (13), wherein
the inhibitor is (2R)-7-bromo-2-[trans-4-
(dimethylamino)cyclohexyl]-N-[(4,6-dimethy1-2-oxo-1,2-
dihydropyridin-3-yl)methy1]-2,4-dimethyl-1,3-
benzodioxole-5-carboxamide, or a pharmaceutically
acceptable salt thereof.
(17) The method according to (12) or (13), wherein
the inhibitor is (2R)-7-chloro-2-[trans-4-
(dimethylamino)cyclohexyl]-N-[(4,6-dimethy1-2-oxo-1,2-
CA 03050221 2019-07-15
=
- 9 -
dihydropyridin-3-yl)methy1]-2,4-dimethyl-1,3-
benzodioxole-5-carboxamide, or a pharmaceutically
acceptable salt thereof.
(18) The method according to (12) or (13), wherein
the inhibitor is (2R)-7-chloro-2-[trans-4-
(dimethylamino)cyclohexyl]-N-[(4,6-dimethy1-2-oxo-1,2-
dihydropyridin-3-yl)methy1]-2,4-dimethyl-1,3-
benzodioxole-5-carboxamide p-toluene sulfonate.
(19) A method for treating HTLV-1-associated
myelopathy in a subject in need thereof, including
administering a therapeutically effective amount of a
compound selected form
N-[(1,2-dihydro-4,6-dimethy1-2-oxo-3-
pyridinyl)methy1]-3-methy1-1-[(1S)-1-methylpropyl]-6-[6-
(1-piperaziny1)-3-pyridiny1]-1H-indole-4-carboxamide,
N-((4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-
yl)methyl)-5-(ethyl(tetrahydro-2H-piran-4-yl)amino)-4-
methy1-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-
carboxamide,
(2R)-7-bromo-2-[trans-4-(dimethylamino)cyclohexyl]-
N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-
2,4-dimethy1-1,3-benzodioxole-5-carboxamide and
(2R)-7-chloro-2-Ftrans-4-(dimethylamino)cyclohexyll-
N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-
2,4-dimethy1-1,3-benzodioxole-5-carboxamide,
or a pharmaceutically acceptable salt thereof, to the
subject.
CA 03050221 2019-07-15
d d
¨ 10 -
- (20) The method according to (19), wherein a
therapeutically effective amount of (2R)-7-bromo-2-
[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethy1-2-
oxo-1,2-dihydropyridin-3-yl)methy1]-2,4-dimethy1-1,3-
benzodioxole-5-carboxamide, or a pharmaceutically
acceptable salt thereof is administered to the subject.
(21) The method according to (19), wherein a
therapeutically effective amount of (2R)-7-chloro-2-
[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethy1-2-
oxo-1,2-dihydropyridin-3-yl)methy1]-2,4-dimethy1-1,3-
benzodioxole-5-carboxamide, or a pharmaceutically
acceptable salt thereof is administered to the subject.
(22) The method according to (19), wherein a
therapeutically effective amount of (2R)-7-chloro-2-
[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethy1-2-
oxo-1,2-dihydropyridin-3-yl)methy1]-2,4-dimethyl-1,3-
benzodioxole-5-carboxamide p-toluene sulfonate is
administered to the subject.
(23) Use of an inhibitor selected from the group
consisting of an EZH1 inhibitor, an EZH2 inhibitor and an
EZH1/2 dual inhibitor, for the manufacture of a
medicament for use in treating HTLV-1-associated
myelopathy.
(24) Use according to (23), wherein the inhibitor is
an EZH1/2 dual inhibitor.
(25) Use according to (23), wherein the inhibitor is
a compound selected from
=
CA 03050221 2019-07-15
- 11 -
N-[(1,2-dihydro-4,6-dimethy1-2-oxo-3-
pyridinyl)methy1]-3-methy1-1-[(1S)-1-methylpropyl]-6-[6-
(1-piperaziny1)-3-pyridiny1]-1H-indole-4-carboxamide,
N-((4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-
yl)methyl)-5-(ethyl(tetrahydro-2H-piran-4-yl)amino)-4-
methy1-41-(morpholinomethyl)-[1,1'-hiphenyl]-3-
carboxamide,
(2R)-7-bromo-2-[trans-4-(dimethylamino)cyclohexyl]-
N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-
2,4-dimethy1-1,3-benzodioxole-5-carboxamide, and
(2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-
N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-
2,4-dimethy1-1,3-benzodioxole-5-carboxamide,
or a pharmaceutically acceptable salt thereof.
(26) Use according to (23) or (24), wherein the
inhibitor is (2R)-7-bromo-2-[trans-4-
(dimethylamino)cyclohexyl]-N-[(4,6-dimethy1-2-oxo-1,2-
dihydropyridin-3-yl)methy1]-2,4-dimethyl-1,3-
benzodioxole-5-carboxamide, or (2R)-7-chloro-2-[trans-4-
(dimethylamino)cyclohexy1]-N-[(4,6-dimethy1-2-oxo-1,2-
dihydropyridin-3-yl)methyl]-2,4-dimethy1-1,3-
benzodioxole-5-carboxamide, or a pharmaceutically
acceptable salt thereof.
(27) Use according to (23) or (24), wherein the
inhibitor is (2R)-7-bromo-2-[trans-4-
(dimethylamino)cyclohexyl]-N-[(4,6-dimethy1-2-oxo-1,2-
dihydropyridin-3-yl)methy1]-2,4-dimethyl-1,3-
CA 03050221 2019-07-15
A
- 12 -
benzodioxole-5-carboxamide, or a pharmaceutically
acceptable salt thereof.
(28) Use according to (23) or (24), wherein the
inhibitor is (2R)-7-chloro-2-[trans-4-
(dimethylamino)cyclohexyl]-N-[(4,6-dimethy1-2-oxo-1,2-
dihydropyridin-3-yl)methy1]-2,4-dimethy1-1,3-
benzodioxole-5-carboxamide, or a pharmaceutically
acceptable salt thereof.
(29) Use according to (23) or (24), wherein the
inhibitor is (2R)-7-chloro-2-qtrans-4-
(dimethylamino)cyclohexyl]-N-[(4,6-dimethy1-2-oxo-1,2-
dihydropyridin-3-yl)methy1]-2,4-dimethyl-1,3-
benzodioxole-5-carboxamide p-toluene sulfonate.
(30) Use of a compound selected from
N-[(1,2-dihydro-4,6-dimethy1-2-oxo-3-
pyridinyl)methy1]-3-methy1-1-[(1S)-1-methylpropyl]-6-[6-
(l-piperaziny1)-3-pyridiny1]-1H-indole-4-carboxamide,
N-((4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-
yl)methyl)-5-(ethyl(tetrahydro-2H-piran-4-yl)amino)-4-
methy1-4'-(morpholinomethyl)-[1,1'-hipheny1]-3-
carboxamide,
(2R)-7-bromo-2-[trans-4-(dimethylamino)cyclohexyl]-
N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-
2,4-dimethy1-1,3-benzodioxole-5-carboxamide, and
(2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-
N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyll-
2,4-dimethy1-1,3-benzodioxole-5-carboxamide,
CA 03050221 2019-07-15
- 13 -
or a pharmaceutically acceptable salt thereof, for
production of a medicament for treating HTLV-1-associated
myelopathy.
(31) Use according to (30) of (2R)-7-bromo-2-[trans-
4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethy1-2-oxo-1,2-
dihydropyridin-3-yl)methy1]-2,4-dimethy1-1,3-
benzodioxole-5-carboxamide, or a pharmaceutically
acceptable salt thereof.
(32) Use according to (30) of (2R)-7-chloro-2-
[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethy1-2-
oxo-1,2-dihydropyridin-3-yl)methy1]-2,4-dimethyl-1,3-
benzodioxole-5-carboxamide, or a pharmaceutically
acceptable salt thereof.
(33) Use according to (30) of (2R)-7-chloro-2-
[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethy1-2-
oxo-1,2-dihydropyridin-3-yl)methy1]-2,4-dimethy1-1,3-
benzodioxole-5-carboxamide p-toluene sulfonate.
Brief Description of Drawings
[0009]
[Figure 1] Figure 1 shows that the level of EZH2 gene
expression is higher in peripheral blood mononuclear
cells (PBMC) taken from the peripheral blood of a HAM
patient than in PBMC of a healthy person.
[Figure 2] Figure 2 shows that compound A and compound B
(defined later), which are EZH1/2 dual inhibitors,
inhibit autoproliferation activity of PBMC
=
CA 03050221 2019-07-15
=
- 14 -
(characteristically seen in HAM) in the absence of any
stimulation.
[Figure 3] Figure 3 shows that E7438 and GSK126, which
are EZH2 inhibitors, inhibit autoproliferation activity
of PBMC (characteristically seen in HAM) in the absence
of any stimulation.
[Figure 4] Figure 4 shows that EZH1/2 dual inhibitors,
compound A and compound B, each enhance release of an
immunosuppressive cytokine, IL-10.
[Figure 5] Figure 5 shows that EZH1/2 dual inhibitors,
compound A and compound B, each reduce HTLV-1 pro-viral
load.
[Figure 6] Figure 6 shows that EZH1/2 dual inhibitors,
compound A and compound B, each reduce the viability of
HTLV-1 infected cells established from the cerebrospinal
fluid of a HAM patient.
[Figure 7] Figure 7 shows that EZH1/2 dual inhibitors,
compound A and compound B, each reduce the viability of
HTLV-1 infected cells established from the cerebrospinal
fluid of a HAM patient, in a concentration-dependent
manner.
[Figure 8] Figure 8 shows that EZH1/2 dual inhibitors,
compound A and compound B, each induce apoptosis of HTLV-
1 infected cells established from the cerebrospinal fluid
of a HAM patient.
[Figure 9] Figure 9 shows that EZH1/2 dual inhibitors,
compound A and compound B, each induce apoptosis of HTLV-
CA 03050221 2019-07-15
- 15 -
1 infected cells established from the cerebrospinal fluid
of a HAM patient, which differs from the patient of
Figure 8.
Detailed Description of the Invention
[0010]
In the specification, the term "subject" refers to a
mammal, particularly a human.
[0011]
In the specification, the term "HTLV-1-associated
myelopathy" (hereinafter sometimes referred to as "HAM")
refers to a disease associated with chronic progressive
spastic spinal paralysis, and diagnosed by a doctor in
accordance with the WHO guidelines (Osame M. Review of
WHO Kagoshima meeting and diagnostic guidelines for
HAM/TSP. In: Blattner W, ed., Human Retrovirology: HTLV.,
New York, New York, USA: Raven Press; 1990: 191-197).
HAM is developed in part of the persons infected
with human T lymphophilic virus type 1 (HTLV-1). In HAM,
a chronic inflammatory process occurs in the spinal cord,
particularly in and around the lower midthorax. In a
spinal cord lesion of HAM, it has been clinically found
that cellular immune response persistently occurs.
From in-situ PCR analysis for HTLV-1 infected cells
in a spinal cord lesion of HAM, HTLV-1 infected cells are
found only in infiltrative T cells and not found in the
peripheral nerve cells or glial cells. From pathological
CA 03050221 2019-07-15
=
- 16 -
analysis for the spinal cord lesion of HAM, it is shown
that the cells mainly constituting infiltrative
inflammatory cells are CD4 positive cells containing
HTLV-1 infected cells, which appear in the early stage of
the disease; however, which are replaced with CD8
positive cells as the disease progresses. From this, HAM
is not considered as a simple infectious disease of the
nerve but considered that immune response mainly mediated
by infiltrated HTLV-1 infected T cells becomes out of
control, with the result that a chronic inflammatory
lesion is formed and/or maintained as a main pathological
condition.
[0012]
Adult T-cell leukemia lymphoma (ATL) is a disease
developed in part of the HTLV-1 infected persons. It is
known that ATL is a malignant tumor (cancer) derived from
HTLV-1 infected cells and completely different from HAM.
HTLV-1 infected cells are considered CD4+0D25+CCR4+ T
cells not only in HAM but also ATL. In HAM, in
CD4+CD25+CCR4+ T cells, expression of Foxp3 decreases and
production of INF-7 is increased (expression of HTLV-1
tax is also high); whereas, regulatory T cells (Treg) are
suppressed. In contrast, in ATL, in CD4+CD25+CCR4+ T
cells, expression of Foxp3 increases (without HTLV-1 tax
expression) and the T cells fall in immunosuppressive
condition. Besides this, Treg function increases.
CA 03050221 2019-07-15
- 17 -
Cellular immune deficiency clinically observed in ATL is
explained by this phenomenon.
As described above, in HAM, immune response
excessively occurs to form a chronic inflammatory lesion,
which is a cause of HAM; whereas, in ATL, immune response
is conversely suppressed.
In short, onset mechanisms of HAM and ATL are
opposite as described above and the cell components
involved therein mutually differ (Araya N., et al.,
Viruses, 3: 1532-1548, 2010).
[0013]
The present inventors found that production of an
immunosuppressive cytokine, IL-10, is increased by
treating HAM patient-derived PBMC with an EZH1/2 dual
inhibitor. The present inventors also found that if HAM
patient-derived PMBC is treated with an EZH2 inhibitor or
an EZH1/2 dual inhibitor, autoproliferation activity of
the PMBC can be suppressed. The present inventors
further found that if HTLV-1 infected cells established
from the cerebrospinal fluid of a HAM patient are treated
with an EZH1/2 dual inhibitor, the viability of cells is
reduced and apoptosis of cells is induced.
Autoproliferation activity of HAM patient-derived PBMC
was more effectively suppressed by an EZH1/2 dual
inhibitor than an EZH2 inhibitor. Since the inhibitory
effect against enzyme activity of EZH2 is equivalent but
the effect of EZH1/2 dual inhibitor is high, it was found
CA 03050221 2019-07-15
- 18 -
that the inhibition against the activity of EZH1 is also
important for suppressing autoproliferation activity of
HAM patient-derived PMBC.
[0014]
Thus, according to the present invention, there is
provided a pharmaceutical composition comprising an
inhibitor selected from the group consisting of an EZH1
inhibitor, an EZH2 inhibitor and an EZH1/2 dual inhibitor
as an active ingredient, for use in treating HTLV-1-
associated mye1opathy.
[0015]
According to the present invention, there is
provided a pharmaceutical composition comprising an EZH1
inhibitor as an active ingredient, for use in treating
HTLV-1-associated myelopathy.
According to the present invention, there is
provided a pharmaceutical composition comprising an EZH2
inhibitor as an active ingredient, for use in treating
HTLV-1-associated myelopathy.
According to the present invention, there is also
provided a pharmaceutical composition comprising an
EZH1/2 dual inhibitor as an active ingredient, for use in
treating HTLV-1-associated myelopathy.
[0016]
The pharmaceutical composition of the present
invention may further comprise an excipient.
[0017]
CA 03050221 2019-07-15
A
- 19 -
Examples of the EZH1 inhibitor that can be used in
the present invention include, but are not particularly
limited to,
(2R)-7-bromo-2-[trans-4-(dimethylamino)cyclohexyl]-
N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-
2,4-dimethy1-1,3-benzodioxole-5-carboxamide,
(2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-
N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-
2,4-dimethy1-1,3-benzodioxole-5-carboxamide and
pharmaceutically acceptable salts of these.
[0018]
Examples of the EZH2 inhibitor that can be used in
the present invention include, but are not particularly
limited to,
N-[(1,2-dihydro-4,6-dimethy1-2-oxo-3-
pyridinyl)methy1]-3-methy1-1-[(1S)-1-methylpropyl]-6-[6-
(1-piperaziny1)-3-pyridiny1]-1H-indole-4-carboxamide,
N-((4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-
yl)methyl)-5-(ethyl(tetrahydro-2H-piran-4-yl)amino)-4-
methy1-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-
carboxamide,
(2R)-7-bromo-2-[trans-4-(dimethylamino)cyclohexyl]-
N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-
2,4-dimethy1-1,3-benzodioxole-5-carboxamide,
(2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-
N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-
2,4-dimethy1-1,3-benzodioxole-5-carboxamide, and
CA 03050221 2019-07-15
- 20 -
pharmaceutically acceptable salts of these. Examples of
the EZH2 inhibitor that can be used in the present
invention include (1S,2R,5R)-5-(4-aminoimidazo[4,5-
c]pyridin-l-y1)-3-(hydroxymethyl)cyclopent-3-en-1,2-diol
and a pharmaceutically acceptable thereof. Examples of
the EZH2 inhibitor that can be used in the present
invention further include N-[(6-methy1-2-oxo-4-propy1-1H-
pyridin-3-yl)methyl]-1-propan-2-y1-6-[6-(4-propan-2-
ylpiperazin-l-yl)pyridin-3-yl]indazole-4-carboxamide and
a pharmaceutically acceptable salt thereof. Examples of
the EZH2 inhibitor further include tazemetostat (EPZ-
6438). Examples of the EZH2 inhibitor that can be used
in the present invention further include N-[(1,2-dihydro-
6-methy1-2-oxo-4-propyl-3-pyridinyl)methy1]-1-)1-
methylethy1)-6-[2-(4-methyl-l-piperaziny1)-4-pyridinyl]-
1H-indazole-4-carboxamide and a pharmaceutically
acceptable salt thereof. Examples of the EZH2 inhibitor
that can be used in the present invention further include
a variety of compounds described in Stazi, G. et al.,
Expert Opinion on Therapeutic Patents, 27: 7, 797-813,
2017. EZH2 inhibitors are developed in the world; for
example, EZH2 inhibitors described in the following
documents can be used in the present invention:
W02014/100646, W02015/057859, W02016/081523,
W02014/144747, W02015/010078, W02015/010049,
W02015/200650, W02015/132765, W02015/004618,
W02016/066697, W02014/124418, W02015/023915,
CA 03050221 2019-07-15
4
- 21 -
W02016/130396, W02015/077193, W02015/077194,
W02015/193768, W02016/073956, W02016/073903,
W02016/102493, W02016/089804, W02014/151369. In the
present invention, the EZH2 inhibitor may further have an
EZH1 inhibitory effect and may be, for example, an EZH1/2
dual inhibitor. For example, the aforementioned N-[(6-
methy1-2-oxo-4-propy1-1H-pyridin-3-yl)methyl]-1-propan-2-
y1-6-[6-(4-propan-2-ylpiperazin-1-y1)pyridin-3-
yl]indazole-4-carboxamide and a pharmaceutically
acceptable salt thereof can be an EZH1/2 dual inhibitor.
In an embodiment of the present invention, both an EZH1
inhibitor and an EZH2 inhibitor may be administered for
treating a patient with HTLV-1-associated myelopathy.
[0019]
Examples of the EZH1/2 dual inhibitor that can be
used in the present invention include, but are not
particularly limited to,
(2R)-7-bromo-2-[trans-4-(dimethylamino)cyclohexyl]-
N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-
2,4-dimethy1-1,3-benzodioxole-5-carboxamide,
(2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-
N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-
2,4-dimethy1-1,3-benzodioxole-5-carboxamide, and
pharmaceutically acceptable salts of these.
[0020]
(2R)-7-Bromo-2-[trans-4-(dimethylamino)cyclohexyl]-
N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-
CA 03050221 2019-07-15
- 22 -
2,4-dimethy1-1,3-benzodioxole-5-carboxamide is disclosed
in W02015/141616, Example 15, and a compound having the
following structure.
[Formula 1]
CH3r:Qrs. ,C H3
I N H
0 N H 0
C H3
Br
0
C H
CI:t(:),,,N, 3
CH3
[0021]
(2R)-7-Chloro-2-[trans-4-(dimethylamino)cyclohexyl]-
N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-
2,4-dimethy1-1,3-benzodioxole-5-carboxamide is disclosed
in W02015/141616, Example 35, and a compound having the
following structure.
[Formula 2]
CH3r:fy.. ,C H3
I NH
0 N H 0
C H3
CI
0
0
C H
CHtOgiN" 3
C H3
CA 03050221 2019-07-15
- 23 -
[0022]
(2R)-7-Chloro-2-[trans-4-(dimethylamino)cyclohexyll-
N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-
2,4-dimethy1-1,3-benzodioxole-5-carboxamide p-toluene
sulfonate is disclosed in W02015/141616, Example 80.
[0023]
N-[(1,2-Dihydro-4,6-dimethy1-2-oxo-3-
pyridinyl)methy1]-3-methy1-1-[(1S)-1-methylpropyl]-6-[6-
(1-piperaziny1)-3-pyridiny1]-1H-indole-4-carboxamide is
also referred to as GSK126, and disclosed in
W02011/140324, Example 270.
[0024]
N-((4,6-Dimethy1-2-oxo-1,2-dihydropyridin-3-
yl)methyl)-5-(ethyl(tetrahydro-2H-piran-4-yl)amino)-4-
methy1-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-
carboxamide is also referred to as E7438 or EPZ-6438, and
disclosed in W02012/142504, Example 44.
[0025]
In an embodiment of the present invention, an EZH1
inhibitor has an inhibitory effect against histone
methyltransferase activity of human EZH1, and ICH
thereof can be 1 RM or less, 500 nM or less, 400 nM or
less, 300 nM or less, 200 nM or less, 150 nM or less, 100
nM or less, 90 nM or less, 80 nM or less, 70 nM or less,
60 nM or less, 50 nM or less, 40 nM or less, 30 nM or
less, 20 nM or less, 15 nM or less, or 10 nM or less.
The value ICH can be determined based on the method
CA 03050221 2019-07-15
- 24 -
described in, for example, W02015/141616, Test Example 1;
for example, by detecting the inhibitory effect against
the activity of EZH1 to transfer S-adenosyl methionine
labeled with tritium to a peptide having an EZH1 target
sequence (for example, a sequence of 12th to 40th amino
acids of a human histone H3 protein; as to the amino acid
sequence of the human histone H3 protein, see, for
example, the sequence registered under GenBank
registration number: CA302546.1). The methyltransferase
activity of EZH1 can be measured by using a PRC2-EZH1
complex.
[0026]
In an embodiment of the present invention, an EZH2
inhibitor has an inhibitory effect against histone
methyltransferase activity of human EZH2, and ICso
thereof can be 1 11M or less, 500 nM or less, 400 nM or
less, 300 nM or less, 200 nM or less, 150 nM or less, 100
nM or less, 90 nM or less, 80 nM or less, 70 nM or less,
60 nM or less, 50 nM or less, 40 nM or less, 30 nM or
less, 20 nM or less, 15 nM or less, or 10 nM or less.
The value IC50 can be determined based on the method
described in, for example, W02015/141616, Test Example 2;
for example, by detecting the inhibitory effect against
the activity of EZH2 to transfer S-adenosyl methionine
labeled with tritium to a peptide having an EZH2 target
sequence (for example, a sequence of 12th to 40th amino
acids of a human histone H3 protein; as to the amino acid
CA 03050221 2019-07-15
- 25 -
sequence of the human histone H3 protein, see, for
example, the sequence registered under GenBank
registration number: CAB02546.1). EZH2 methyltransferase
activity can be measured by using a PRC2-EZH2 complex.
[0027]
In an embodiment of the present invention, an EZH1/2
dual inhibitor has an inhibitory effect against histone
methyltransferase activity of human EZH1, and ICH
thereof can be 1 RM or less, 500 nM or less, 400 nM or
less, 300 nM or less, 200 nM or less, 150 nM or less, 100
nM or less, 90 nM or less, 80 nM or less, 70 nM or less,
60 nM or less, 50 nM or less, 40 nM or less, 30 nM or
less, 20 nM or less, 15 nM or less, or 10 nM or less, and,
has an inhibitory effect against histone
methyltransferase activity of human EZH2, and IC50
thereof can be 1 M or less, 500 nM or less, 400 nM or
less, 300 nM or less, 200 nM or less, 150 nM or less, 100
nM or less, 90 nM or less, 80 nM or less, 70 nM or less,
60 nM or less, 50 nM or less, 40 nM or less, 30 nM or
less, 20 nM or less, 15 nM or less, or 10 nM or less.
The values IC50 for EZH1 and EZH2 each can he determined
as mentioned above.
[0028]
In an embodiment of the present invention, GI50 of an
EZH1 inhibitor against HCT-4 cell line established from a
patient with 1-ITLV-1-associated myelopathy can be 1 RM or
less, 500 nM or less, 400 nM or less, 300 nM or less, 200
CA 03050221 2019-07-15
- 26 -
nM or less, 150 nM or less, 100 nM or less, 90 nM or less,
80 nM or less, 70 nM or less, 60 nM or less, 50 nM or
less, 40 nM or less, 30 nM or less, 20 nM or less, 15 nM
or less, or 10 nM or less. In the specification, "G150"
refers to the concentration of a drug required for
attaining a half of a maximum growth inhibitory activity
of the drug.
[0029]
In an embodiment of the present invention, GI50 of an
EZH2 inhibitor against HCT-4 cell line established from a
patient with HTLV-1-associated myelopathy can be 1 M or
less, 500 nM or less, 400 nM or less, 300 nM or less, 200
nM or less, 150 nM or less, 100 nM or less, 90 nM or less,
80 nM or less, 70 nM or less, 60 nM or less, 50 nM or
less, 40 nM or less, 30 nM or less, 20 nM or less, 15 nM
or less, or 10 nM or less.
[0030]
In an embodiment of the present invention, GI50 of an
EZH1/2 dual inhibitor against HCT-4 cell strain
established from a patient with HTLV-1-associated
myelopathy can be 1 M or less, 500 nM or less, 400 nM or
less, 300 nM or less, 200 nM or less, 150 nM or less, 100
nM or less, 90 nM or less, 80 nM or less, 70 nM or less,
60 nM or less, 50 nM or less, 40 nM or less, 30 nM or
less, 20 nM or less, 15 nM or less, or 10 nM or less.
[0031]
CA 03050221 2019-07-15
- 27 -
A compound of the present invention can be a
pharmaceutically acceptable salt thereof, if desired.
The pharmaceutically acceptable salt refers to a salt,
which does not have significant toxicity and can be used
as a medicament. The compound of the present invention
has a basic group, and thus, formed into a salt by
reacting it with an acid.
[0032]
Examples of a salt based on a basic group include
hydrohalides such as a hydrofluoric acid salt, a
hydrochloride, a hydrobromide and a hydroiodide;
inorganic acid salts such as nitrate, perchlorate,
sulfate and phosphate; Ci-C6 alkyl sulfonates such as
methanesulfonate, trifluoromethanesulfonate and
ethanesulfonate; aryl sulfonates such as benzene
sulfonate and p-toluene sulfonate; organic acid salts
such as an acetate, a malate, a fumarate, a succinate,
citrate, ascorbate, tartrate, borate, adipate and
maleate; and amino acid salts such as a glycine salt, a
lysine salt, an arginine salt, an ornithine salt, a
glutamate and an aspartate.
[0033]
A pharmaceutically acceptable salt of a compound of
the present invention sometimes takes up a water molecule
and changes into a hydrate when it is left in the air or
reprecipitated. Such a hydrate is also included in the
salt of the present invention.
CA 03050221 2019-07-15
- 28 -
[0034]
A pharmaceutically acceptable salt of a compound of
the present invention sometimes absorbs a solvent and
changes into as a solvate when it is left in a solvent or
reprecipitated. Such a solvate is also included in the
salt of the present invention.
[0035]
The present invention includes a compound, which is
converted into compound A or compound B serving as an
active ingredient of the pharmaceutical composition of
the present invention, through a reaction with, e.g., an
enzyme or gastric acid in the in-vivo physiological
conditions, in other words, a compound converted into
compound A or compound B by, e.g., an enzymatic oxidation,
reduction or hydrolysis, or "a pharmaceutically
acceptable prodrug compound", which is to be converted
into compound A or compound B by hydrolysis with, e.g.,
gastric acid.
[0036]
The compound of the present invention or a
pharmaceutically acceptable salt thereof can be isolated
and purified by a method known in the art, such as
extraction, precipitation, distillation, chromatography,
separation by precipitation and reprecipitation.
[0037]
The compound of the present invention may contain an
atomic isotope as at least one atom constituting the
CA 03050221 2019-07-15
- 29 -
compound in a non-naturally occurring ratio. As the
atomic isotope, e.g., deuterium (2H), tritium (3H),
iodine-125 (1251) or carbon-14 ('4C) is mentioned. The
compound can be labelled with a radioactive isotope such
as tritium (3H), iodine-125 (1251) or carbon-14 (It). The
compound labeled with a radioactive isotope is useful as
a therapeutic or prophylactic agent, a research reagent
such as an assay reagent, and a diagnostic agent such as
an in-vivo diagnostic imaging agent. All isotopic
variants of a compound of the present invention are
included in the range of the present invention
irrespective of whether they are radioactive or not.
[0038]
A compound of the present invention or a
pharmaceutically acceptable salt thereof can be
administered by various administration methods. The
administration methods include, oral administration, e.g.,
administration of tablets, capsules, granules, emulsions,
pills, powders and syrups (liquid formulation), or
parenteral administration, e.g., administration by
injections (intravenous, intramuscle, subcutaneous or
intraperitoneal administration), drip agents and
suppositories (rectal administration). These various
preparations can be prepared by using a main drug and
additives which are ordinarily used in the technical
field of medicinal preparation, such as an excipient, a
CA 03050221 2019-07-15
- 30 -
binder, a disintegrant, a lubricant, a flavoring agent, a
solubilizer, a suspending agent and a coating agent.
[0039]
If tablets are prepared, examples of a carrier that
can be used include an excipient such as lactose, white
sugar, sodium chloride, glucose, urea, starch, calcium
carbonate, kaolin, crystalline cellulose and silica; a
binder such as water, ethanol, propanol, simple syrup, a
glucose solution, a starch solution, a gelatin solution,
carboxymethylcellulose, shellac, methyl cellulose,
potassium phosphate and polyvinyl pyrrolidone; a
disintegrant such as dry starch, sodium alginate, agar
powder, laminaran powder, sodium hydrogen carbonate,
calcium carbonate, polyoxyethylene sorbitan fatty acid
ester, sodium lauryl sulfate, monoglyceryl stearate,
starch and lactose; a collapse suppressor such as white
sugar, stearin, cocoa butter and hydrogenated oil; an
absorption promoter such as a quaternary ammonium salt
and sodium lauryl sulfate; a moisturizer such as glycerin
and starch; an adsorbent such as starch, lactose, kaolin,
bentonite and colloidal silicic acid; and a lubricant
such as purified talc, stearate, oxalic acid powder and
polyethylene glycol. If necessary, tablets coated with
an ordinary film such as sugar coated tablets, gelatin
encapsulated tablets, enteric coated tablets and film
coated tablets or double-layer tablets and multilayer
tablets can be used.
CA 03050221 2019-07-15
- 31 -
[0040]
If pills are prepared, examples of a carrier thereof
that can be used include an excipient such as glucose,
lactose, cocoa butter, starch, hydrogenated vegetable oil,
kaolin and talc; a binder such as gum Arabic, tragacanth
powder, gelatin and ethanol; and a disintegrant such as
laminaran and agar.
If a suppository is prepared, a wide variety of
substances known in this field can be used as a carrier.
Examples of the carrier include polyethylene glycol,
cocoa butter, a higher alcohol, an ester of a higher
alcohol, gelatin and semi-synthetic glyceride.
[0041]
If an injection is prepared, a liquid formulation,
an emulsion or a suspending agent can be used. The
liquid formulation, emulsion or suspending agent is
preferably sterilized and isotonic to blood. A solvent
to be used for producing the liquid formulation, emulsion
or suspending agent is not particularly limited as long
as it is used as a diluent for medical use. Examples of
the solvent include water, ethanol, propylene glycol, an
ethoxylated isostearyl alcohol, a polyoxylated isostearyl
alcohol and a polyoxyethylene sorbitan fatty acid ester.
Note that, in this case, a salt, glucose or glycerin may
be contained in a sufficient amount for preparing an
isotonic solution, and, e.g., a solubilizer, a buffer and
CA 03050221 2019-07-15
=
- 32 -
a soothing agent, which are ordinarily used, may be
contained.
[0042]
The aforementioned preparation, if necessary, may
contain, e.g., a colorant, a preservative, an aroma
chemical, a flavor agent and a sweetener, and another
medical drug can be further contained.
[0043]
The amount of a compound serving as an active
ingredient of the aforementioned preparation is not
particularly limited and appropriately selected from a
wide range. The amount is usually 0.5 to 70 wt%,
preferably 1 to 30 wt% of the whole composition
(preparation).
[0044]
The use amount (dosage) of the compound varies
depending on the symptom and age of a patient (warm-
blooded animal, particularly human). In the case of oral
administration, the upper limit of the dosage is 2000 mg
(preferably, 100 mg) and the lower limit is 0.1 mg
(preferably, 1 mg, further preferably, 10 mg) per day per
adult. Administration can be made 1 to 6 times per day
depending on the symptom.
[0045]
The pharmaceutical composition of the present
invention can be used in combination with another HAM
therapeutic agent. Examples of the HAM therapeutic agent
CA 03050221 2019-07-15
=
- 33 -
to be used in combination include, but are not
particularly limited to, adrenocortical hormone,
prednisolone, interferon-a, azathioprine,
salazosulfapyridine, ascorbic acid, pentoxifylline,
Lactobacillus casei Shirota (Yakult 400), erythromycin,
mizoribine, fosfomycin, griseall, human immunoglobulin,
danazol and eperisone hydrochloride.
[0046]
Accordingly, in the present invention, there is
provided a pharmaceutical composition comprising an
inhibitor selected from the group consisting of an EZH1
inhibitor, an EZH2 inhibitor and an EZH1/2 dual inhibitor
as an active ingredient, for use in treating HTLV-1-
associated myelopathy, and to be used in combination with
another HAM therapeutic agent as mentioned above. In the
present invention, there is provided a combined drug
comprising an inhibitor selected from the group
consisting of an EZH1 inhibitor, an EZH2 inhibitor and an
EZH1/2 dual inhibitor and at least one of the HAM
therapeutic agents mentioned above, for use in treating
HTLV-1-associated myelopathy.
[0047]
According to the present invention, there is
provided use of an inhibitor selected from the group
consisting of an EZH1 inhibitor, an EZH2 inhibitor and an
EZH1/2 dual inhibitor, for the manufacture of a
CA 03050221 2019-07-15
- 34 -
medicament for use in treating HTLV-1-associated
myelopathy.
According to the present invention, there is
provided use of an EZH1 inhibitor for the manufacture of
a medicament for use in treating HTLV-1-associated
myelopathy.
According to the present invention, there is
provided use of an EZH2 inhibitor for the manufacture of
a medicament for use in treating HTLV-1-associated
myelopathy.
According to the present invention, there is
provided use of an EZH1/2 dual inhibitor for the
manufacture of a medicament for use in treating HTLV-1-
associated myelopathy.
[0048]
According to the present invention, there is
provided use of a compound selected from
(2R)-7-bromo-2-[trans-4-(dimethylamino)cyclohexyl]-
N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-
2,4-dimethy1-1,3-benzodioxole-5-carboxamide, and
(2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-
N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-
2,4-dimethy1-1,3-benzodioxole-5-carboxamide and
pharmaceutically acceptable salts of these for the
manufacture of a medicament for use in treating HTLV-1-
associated myelopathy.
[0049]
CA 03050221 2019-07-15
- 35 -
According to the present invention, there is
provided use of a compound selected from
N-[(1,2-dihydro-4,6-dimethy1-2-oxo-3-
pyridinyl)methy1]-3-methy1-1-[(1S)-1-methylpropyl]-6-[6-
(1-piperaziny1)-3-pyridiny1]-1H-indole-4-carboxamide,
N-((4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-
yl)methyl)-5-(ethyl(tetrahydro-2H-piran-4-yl)amino)-4-
methy1-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-
carboxamide,
(2R)-7-bromo-2-[trans-4-(dimethylamino)cyclohexyl]-
N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-
2,4-dimethy1-1,3-benzodioxole-5-carboxamide, and
(2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-
N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-
2,4-dimethy1-1,3-benzodioxole-5-carboxamide, and
pharmaceutically acceptable salts of these, for the
manufacture of a medicament for use in treating HTLV-1-
associated myelopathy.
[0050]
In a preferable embodiment of the present invention,
as a pharmaceutically acceptable salt of EHZ1/2 dual
inhibitor, i.e., (2R)-7-chloro-2-[trans-4-
(dimethylamino)cyclohexyl]-N-[(4,6-dimethy1-2-oxo-1,2-
dihydropyridin-3-yl)methy1]-2,4-dimethyl-1,3-
benzodioxole-5-carboxamide, (2R)-7-chloro-2-[trans-4-
(dimethylamino)cyclohexyl]-N-[(4,6-dimethy1-2-oxo-1,2-
dihydropyridin-3-yl)methy1]-2,4-dimethyl-1,3-
CA 03050221 2019-07-15
- 36 -
benzodioxole-5-carboxamide p-toluene sulfonate, can be
used, for treatment of HTLV-1-associated myelopathy or
the manufacture of a medicament for treating HTLV-1-
associated myelopathy.
[0051]
According to the present invention, there is
provided a method for treating HTLV-1-associated
myelopathy in a subject suffering from HTLV-1-associated
myelopathy, including administering, to the subject, a
therapeutically effective amount of an inhibitor selected
from the group consisting of an EZH1 inhibitor, an EZH2
inhibitor and an EZH1/2 dual inhibitor.
[0052]
According to the present invention, there is
provided a method for treating HTLV-1-associated
myelopathy in a subject suffering from HTLV-1-associated
myelopathy, including administering, to the subject, a
therapeutically effective amount of a compound selected
from
N-[(1,2-dihydro-4,6-dimethy1-2-oxo-3-
pyridinyl)methy1]-3-methy1-1-[(15)-1-methylpropyl]-6-[6-
(1-piperaziny1)-3-pyridiny1]-1H-indole-4-carboxamide,
N-((4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-
yl)methyl)-5-(ethyl(tetrahydro-2H-piran-4-yl)amino)-4-
methy1-41-(morpholinomethyl)-[1,1'-biphenyl]-3-
carboxamide,
CA 03050221 2019-07-15
- 37 -
(2R)-7-bromo-2-[trans-4-(dimethylamino)cyclohexyl]-
N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-
2,4-dimethy1-1,3-benzodioxole-5-carboxamide, and
(2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-
N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-
2,4-dimethy1-1,3-benzodioxole-5-carboxamide and
pharmaceutically acceptable salts of these.
[0053]
According to the present invention, there is
provided an immunosuppressant comprising an inhibitor
selected from the group consisting of an EZH1 inhibitor,
an EZH2 inhibitor and an EZH1/2 dual inhibitor.
According to the present invention, there is provided an
inhibitor selected from the group consisting of an EZH1
inhibitor, an EZH2 inhibitor and an EZH1/2 dual inhibitor
for use in suppressing immunity.
According to the present invention, there is
provided use of an inhibitor selected from the group
consisting of an EZH1 inhibitor, an EZH2 inhibitor and an
EZH1/2 dual inhibitor, for the manufacture of a
medicament for use in suppressing immunity. According to
the present invention, there is provided a method for
suppressing immunity in a subject in need thereof,
including administering, to the subject, a
therapeutically effective amount of an inhibitor selected
from the group consisting of an EZH1 inhibitor, an EZH2
inhibitor and an EZH1/2 dual inhibitor.
CA 03050221 2019-07-15
- 38 -
In each of the embodiments regarding suppression of
immunity, an inhibitor as mentioned above can be
administered to a subject suffering from HTLV-1-
associated myelopathy. In each of the embodiments,
suppression of immunity can be suppression of
inflammation enhanced in a subject suffering from HTLV-1-
associated myelopathy. In each of the embodiments, the
aforementioned inhibitors are mentioned as the EZH1
inhibitor, EZH2 inhibitor and EZH1/2 dual inhibitor and
can be used in the present invention.
[0054]
According to the present invention, there is also
provided a pharmaceutical composition comprising an
inhibitor selected from the group consisting of an EZH1
inhibitor, an EZH2 inhibitor and an EZH1/2 dual inhibitor
for use in enhancing the yield of IL-10 in a subject.
According to the present invention, there is provided an
inhibitor selected from the group consisting of an EZH1
inhibitor, an EZH2 inhibitor and an EZH1/2 dual inhibitor
for use in enhancing the yield of IL-10. According to
the present invention, there is provided use of an
inhibitor selected from the group consisting of an EZH1
inhibitor, an EZH2 inhibitor and an EZH1/2 dual inhibitor,
for the manufacture of a medicament for use in enhancing
the yield of IL-10. According to the present invention,
there is provided a method for enhancing of the yield of
IL-10 in a subject in need thereof, including
CA 03050221 2019-07-15
- 39 -
administering, to the subject, a therapeutically
effective amount of an inhibitor selected from the group
consisting of an EZH1 inhibitor, an EZH2 inhibitor and an
EZH1/2 dual inhibitor.
In each of the embodiments regarding enhancement of
IL-10 yield, an inhibitor as mentioned above can be
administered to, for example, a subject suffering from
HTLV-1-associated myelopathy. In each of the embodiments,
the inhibitors as mentioned above can be used as the EZH1
inhibitor, EZH2 inhibitor and EZH1/2 dual inhibitor in
the present invention.
[0055]
According to the present invention, there is also
provided a pharmaceutical composition comprising an
inhibitor selected from the group consisting of an EZH1
inhibitor, an EZH2 inhibitor and an EZH1/2 dual inhibitor,
for use in suppressing proliferation activity of PBMC in
a subject (for example, a subject suffering from HTLV-1-
associated myelopathy). According to the present
invention, there is provided an inhibitor selected from
the group consisting of an EZH1 inhibitor, an EZH2
inhibitor and an EZH1/2 dual inhibitor for use in
suppressing proliferation activity of PBMC in a subject
(for example, a subject suffering from HTLV-1-associated
myelopathy). According to the present invention, there
is provided use of an inhibitor selected from the group
consisting of an EZH1 inhibitor, an EZH2 inhibitor and an
CA 03050221 2019-07-15
3
- 40 -
EZH1/2 dual inhibitor, for the manufacture of a
medicament for use in suppressing proliferation activity
of PBMC in a subject (for example, a subject suffering
from HTLV-1-associated myelopathy). According to the
present invention, there is provided a method for
suppressing proliferation activity of PBMC in a subject
(for example, a subject suffering from HTLV-1-associated
myelopathy) in need thereof, including administering, to
the subject, a therapeutically effective amount of an
inhibitor selected from the group consisting of an EZH1
inhibitor, an EZH2 inhibitor and an EZH1/2 dual inhibitor.
In the embodiment, the proliferation activity of PBMC can
be HTLV-1 infected cell inductive self-proliferation
activity. In the embodiment, the proliferation activity
of PBMC can be autoproliferation activity in the absence
of proliferation stimulation. In the embodiment, CD4+
single positive T cell and/or CD8+ single positive T cell
can be included in PBMC. In the embodiment,
CD4+0D25+CCR4+ T cell can be included in PBMC.
In each of these embodiments regarding suppression
of PBMC proliferation activity, an inhibitor as mentioned
above can be administered to, for example, a subject
suffering from HTLV-1-associated myelopathy. In each of
the embodiments, the inhibitors as mentioned above are
mentioned as the EZH1 inhibitor, EZH2 inhibitor and
EZH1/2 dual inhibitor and can be used in the present
invention.
CA 03050221 2019-07-15
- 41 -
[0056]
According to the present invention, there is
provided a pharmaceutical composition comprising an
inhibitor selected from the group consisting of an EZH1
inhibitor, an EZH2 inhibitor and an EZH1/2 dual inhibitor
for use in inducing apoptosis of HTLV-1 infected cells.
According to the present invention, there is provided an
inhibitor selected from the group consisting of an EZH1
inhibitor, an EZH2 inhibitor and an EZH1/2 dual inhibitor
for use in inducing apoptosis of HTLV-1 infected cells.
According to the present invention, there is provided use
of an inhibitor selected from the group consisting of an
EZH1 inhibitor, an EZH2 inhibitor and an EZH1/2 dual
inhibitor, for the manufacture of a medicament for use in
inducing apoptosis of HTLV-1 infected cells. In the
present invention, there is provided a method for
inducing apoptosis of HTLV-1 infected cells in a subject
(for example, a subject suffering from HTLV-1-associated
myelopathy) in need thereof, including administering, to
the subject, a therapeutically effective amount of an
inhibitor selected from the group consisting of an EZH1
inhibitor, an EZH2 inhibitor and an EZH1/2 dual inhibitor.
In each of these embodiments regarding induction of
apoptosis of HTLV-1 infected cells, HTLV-1 infected cells
are present in the body of a subject suffering from HTLV-
1-associated myelopathy. In each of these embodiments,
an inhibitor as mentioned above can be administered to,
CA 03050221 2019-07-15
- 42 -
for example, a subject suffering from HTLV-1-associated
myelopathy. In each of the embodiments, inhibitors as
mentioned above are mentioned as EZH1 inhibitor, EZH2
inhibitor and EZH1/2 dual inhibitor and can be used in
the present invention.
Examples
[0057]
(2R)-7-bromo-2-[trans-4-(dimethylamino)cyclohexyl]-
N-[(4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl]-
2,4-dimethy1-1,3-benzodioxole-5-carboxamide will be
referred to as compound A. Also, (2R)-7-chloro-2-[trans-
4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethy1-2-oxo-1,2-
dihydropyridin-3-yl)methy1]-2,4-dimethyl-1,3-
benzodioxole-5-carboxamide will be referred to as
compound B.
Compound A was synthesized in accordance with the
description of W02015/141616, Example 15. Compound B was
synthesized in accordance with the description of
W02015/141616, Example 35. In the following Examples,
compounds A and B thus synthesized were used.
Note that, compounds A and B inhibit enzyme
activities of both EZH1 and EZH2 (W02015/141616).
[0058]
In the following Examples, HAM/TSP patients were
diagnosed by a doctor in accordance with the WHO
diagnostic criteria (Osame M. Review of WHO Kagoshima
CA 03050221 2019-07-15
- 43 -
meeting and diagnostic guidelines for HAM/TSP In:
Blattner W, ed. Human Retrovirology: HTLV. New York,
New York, USA: Raven Press; 1990: 191-197).
[0059]
Example 1: Increase of EZH2 expression level in HAM cells
In this Example, the peripheral blood mononuclear
cells (PBMC) obtained from HAM patients and PBMC obtained
from healthy persons will be subjected to gene expression
analysis to demonstrate that EZH2 expression level is
elevated in the HAM patient-derived PMBC.
[0060]
From the peripheral blood mononuclear cells
(Peripheral Blood Mononuclear Cell: PBMC) separated from
peripheral blood of 5 HAM patients, CD4+ cells were
separated by use of a human CD4+ isolation kit (Miltenyi
Biotec), and thereafter, CD4+CCR4+ cells were separated
by use of Anti-mouse IgG1 MicroBeads (Miltenyi Biotec) to
which an anti-CCR4 antibody (BD 551121) was bound. In
the CD4+CCR4+ cell fraction, HTLV-1 infected cells are
contained. 0D4+CCR4+ cells were separated in the same
manner as above from PBMC of 5 healthy persons and used
as a control group. From the CD4+CCR4+ cells separated,
total RNA was obtained and cDNA was prepared by use of
ReverTra Ace (Toyobo Co., Ltd). Using cDNA thus prepared,
difference in gene expression between the HAM patient-
derived CD4+CCR4+ cells and healthy person-derived
CD4+CCR4+ cells was cyclopaedically analyzed by
CA 03050221 2019-07-15
- 44 -
microarray analysis. As a result, it was found that EZH2
expression level differs. Then, the difference in EZH2
expression level was more specifically analyzed by Real
time PCR. The primer set used for detection of EZH2
expressed was: EZH2#35-F: TGTGGATACTCCTCCAAGGAA and
EZH2#35-R: GAGGAGCCGTCCTTTTTCA; the probe used herein was
Universal ProbeLibrary 035 (Roche). A significance test
was carried out in accordance with a paired t-test of
GraphPad Prism6 (MDF). The results were as shown in
Figure 1.
[0061]
As shown in Figure 1, expression of EZH2 mRNA in the
HAM patient-derived 0D4+CCR4+ cells (HAM-CD4+CCR4+) was
significantly high, i.e., 2.6 times as high as in healthy
person-derived CD4+CCR4+ cells (HD-CD4+CCR4+). From the
results, it was demonstrated that the EZH2 expression in
HAM patient-derived infected cells is higher than the
healthy person-derived cells.
Interestingly, the EZH2 expression level in CD4+ T
cells other than HTLv-1 infected cells was high.
[0062]
Example 2: Effect of EZH1/2 dual inhibitor on HAM
HAM patient-derived PBMC have a feature not seen in
other PBMC in that the cells spontaneously proliferate by
culturing them in the absence of any stimulation.
[0063]
CA 03050221 2019-07-15
- 45 -
Then, using HAM patient-derived PBMC, the effect of
the EZH1/2 dual inhibitor was examined. As the EZH1/2
dual inhibitor, compound A and compound B were used.
The effects of compound A and compound B were
evaluated based on (1) autoproliferation activity; (2)
change in yield of inflammatory suppression cytokine IL-
(Example 3, later described); and (3) change in number
of HTLV-1 infected cells (Example 4, later described) in
HAM patient's PBMC. In the evaluation time, a group
treated with DMSO and a group treated with prednisolone
(PSL, 1 g/ml) were used as controls. PSL having an
inflammatory suppression action can suppress
autoproliferation activity of the HAM patient's PBMC;
however, PSL does not exhibit infected cell removal
activity in this experimental system or clinical sites.
[0064]
Suppressive effects of compound A and compound B on
excessive immune response of HAM patient-derived PBMC
PBMC taken from 8 HAM patients were suspended in
culture mediums (RPMI1640 culture medium (wako)
containing 10% FBS (GIBCO)), seeded in a 96-well round-
bottom plate in a ratio of 1 x 105 cells per well (3
wells were used for each concentration), and compound A
or compound B was added so as to provide a final
concentration of 1, 10, 100 or 1000 nM. Culture was
carried out at 37 C in 5% CO2 conditions for 6 days. The
DMSO treatment group and the PSL (1 pg/mL) treatment
85294106
- 46 -
group were used as controls. Day 6 after initiation of
culture, 1 Ci 3H-thymidine was added to each well and
culture was carried out at 37 C, in 5% CO2 conditions for
16 hours. Thereafter, the cultured cells were allowed to
adsorb to a glass filter (Printed Filtermat A,
PerkinElmer) by a cell harvester (Tomtec MH3,
PerkinElmer), dried and impregnated with solid
TM
scintillator Meltilex-A (PerkinElmer). The amount of the
3H-thymidine incorporated in the cells was measured by
TM
use of MicroBeta (WALLAC MicroBeta TriLux 1450-021)
(Yamano et al., PLoS One. 2009, 4(8): e6517). Based on
the average count of 3H-thymidine in the DMS0 treatment
group of HAM patients' PBMC as 100%, the relative values
of the groups treated with compound A, compound B and PSL
(1 g/mL) were obtained by calculation, and then, an
average value of 8 HAM patient cases was obtained. A
significance test was carried out in accordance with the
TM
Friedman test of GraphPad Prism6 (MDF). The results were
as shown in Figure 2, upper panel.
[0065]
As shown in Figure 2, upper panel, both compound A
and compound B suppressed autoproliferation activity of
PBMC in all the eight HAM patient cases, in a
concentration-dependent manner. Based on the average of
all the cases used in the experiment, a statistically
significant suppression effect was observed in either
case of the treatment with compound A or compound B (100
Date Recue/Date Received 2020-11-10
CA 03050221 2019-07-15
- 47 -
nM or more). At this time, G150 of compound A was 73.0 nM
and GI50 of compound B was 33.9 nM. Thus, it was
suggested that the EZH1/2 dual inhibitor has an effect of
suppressing excessive immune response of HAM patient-
derived PBMC.
The number of patients was increased to 16 and the
same experiment as above was carried out. The results
are shown in Figure 2, lower panel. Based on the results
of 16 HAM patients on spontaneous proliferation activity,
GI50 of compound A was 45.6 nM and G150 of compound B was
25.9 nM.
[0066]
In either one of the experiments, as shown in the
upper panel and lower panel of Figure 2, even in a low
concentration region of 100 nM or less, inhibitory
actions of compound A and B against spontaneous
proliferation activity of HAM patient-derived PMBC were
observed.
[0067]
Suppressive Effect of EZH2 inhibitor on excessive immune
response of HAM patient-derived PBMC
Effect on HAM patient-derived PBMC was checked in
the same manner as in the above Example except that an
EZH2 inhibitor was used in place of compounds A and B.
[0068]
As the EZH2 inhibitor, GSK126 (CAS No.: 1346574-57-
9) and E7438 (CAS No.: 1403254-99-8) were used. The
CA 03050221 2019-07-15
- 48 -
concentration for treatment was 1, 10, 100, 1000 or 10000
nM in terms of final concentration. In the experiment,
PBMC samples taken from the 8 persons before the number
of cases increased in the above were used. The results
were as shown in Figure 3.
[0069]
As shown in Figure 3, it was confirmed that E7438
(Figure 3, upper panel) and GSK126 (Figure 3, lower
panel) each suppress autoproliferation activity of HAM
patient-derived PBMC. GI50 of E7438 was 214.2 nM and GI50
of GSK126 was 724.3 nM.
As described above, suppressive actions of E7438 and
GSK126 against spontaneous proliferation activity of HAM
patient-derived PBMC were observed in a low-concentration
region of 1 M or less.
[0070]
The magnitudes of inhibitory effects of the EZH1/2
dual inhibitor and the EZH2 inhibitor used in this
Example on enzyme activity of EZH2 are not significantly
different. Accordingly, it is understood that not only
inhibition of EZH2 but also inhibition of EZH1 has a
strongly influence inhibitory effect on spontaneous
proliferation activity of HAM patient-derived PBMC.
[0071]
Example 3: Production of inflammatory suppressive
cytokine IL-10 induced by EZH1/2 dual inhibitor
CA 03050221 2019-07-15
- 49 -
The pathological condition of HAM is characterized
by inflammation induced by PBMC. Thus, in this Example,
the effect of an EZH1/2 dual inhibitor on release of a
cytokine from PBMC was examined.
[0072]
PBMC taken from 8 HAM patients were suspended in a
culture medium (RPMI1640 culture medium containing 10%
FBS), seeded in a 48-well plate in a ratio of 5 x 105
cells per well and a compound A or compound B was added
so as to provide a final concentration of 1, 10, 100 or
1000 nM. The culture solution of 0.5 mL in total was
cultured at 37 C in 5% CO2 conditions for 12 days. A
group treated with DMSO and a group treated with PSL (1
g/mL) were used as controls. Day 12 after initiation of
the culture, the culture solution was centrifuged, and
thereafter, the culture supernatant alone was recovered.
The concentration of IL-10 in the culture supernatant was
determined by use of the Cytokine Beads Array kit (BD
Biosciences) and a flow cytometer FACSCantoII (BD
Biosciences) (Yamauchi et al., J Infect Dis. 2015, 211
(2): 238-48). Based on the IL-10 concentration in the
culture solution of the DMSO treatment group as 100%,
changes in IL-10 concentration of culture solutions of
groups treated with compound A and compound B different
in concentration or a group treated with PSL (1 g/mL)
were compared. The significance test was carried out by
CA 03050221 2019-07-15
- 50 -
using the Friedman test of GraphPad Prism6 (MDF). The
results were as shown in Figure 4.
[0073]
As shown in Figure 4, the yield of IL-10 from PBMC
was dramatically increased by each of compound A and
compound B; and more specifically, it was found that the
yield of the IL-10 production (acceleration) is the same
or more even at a concentration of about 1/10 as low as
PSL, which is known as an inflammatory suppression agent.
From the above, it was suggested that compound A and
compound B act on HAM patient-derived PBMC and suppress
inflammation, which is a main pathological condition of
HAM.
In contrast, no significant change in yields of INF-
a, INF-a and IL-6 amount was observed.
[0074]
HAM patient-derived PBMC has autoproliferation
activity in the absence of any stimulation. The
autoproliferation activity is conceivably produced by
excessive response of the immune system caused by HAM
infection cells. Example 3 demonstrated that an EZH1/2
dual inhibitor causes HAM patient-derived PBMC to produce
IL-10 having an immunosuppressive action. The
possibility that the EZH1/2 dual inhibitor might suppress
excessive response of the immune system through IL-10
having an immunosuppressive action, thereby inhibiting
spontaneous proliferation activity of PBMC, is suggested.
CA 03050221 2019-07-15
- 51 -
[0075]
Example 4: Effect of EZH1/2 dual inhibitor on removal of
HTLV-1 infected cells from HAM patient-derived PMBC
In this Example, whether or not an EZH1/2 dual
inhibitor has an effect on removal of HTLV-1 infected
cells causing HAM was examined.
[0076]
PBMC taken from 8 HAM patients were suspended in a
culture medium (RPMI1640 culture medium containing 10%
FBS) and seeded in a 48-well plate in a ratio of 5 x 105
cells per well, and compound A or compound B was added so
as to provide a final concentration of 1, 10, 100 or 1000
nM. The culture solution of 0.5 mL in total was cultured
at 37 C in 5% CO2 conditions for 12 days. A group treated
with DMSO and a group treated with PSL (1 gg/mL) were
used as controls. Day 12 after initiation of culture,
the culture solution was centrifuged, and thereafter, the
cell suspension was recovered from each of the cultures
carried out under different conditions and centrifuged.
After the supernatant was removed, the cell pellet was
subjected to genomic DNA extraction. The genome DNA
extracted was subjected to real time PCR to measure HTLV-
1 pro-viral load (infected cell rate) (Yamano et al.,
Blood. 2002, 99 (1): 88-94). Based on the HTLV-1 pro-
viral load in cells, which were obtained by adding DMSO
to each of the HAM patient's PBMC and culturing the PBMC,
as 100%, the relative value of HTLV-1 pro-viral load in a
0
CA 03050221 2019-07-15
=
- 52 -
group treated with compound A, compound B or PSL was
calculated, and then, an average value of 8 HAM patient
cases was obtained. The significance test was carried
out by using the Friedman test of GraphPad Prism6 (MDF).
The results were as shown in Figure 5.
[0077]
As shown in Figure 5, it was found that HTLV-1 pro-
viral load in the HAM patient's PBMC decreases by the
treatment with compound A or compound B in 5 out of 8
cases. Based on the average value of all HAM patients
used in the experiment, a significant reduction in pro-
viral load was confirmed in the cases treated with 1000
nM compound A or compound B.
[0078]
Example 5: Effect of EZH1/2 dual inhibitor on HTLV-1
infected cells
In this Example, effect of an EZH1/2 dual inhibitor
on proliferation of a HTLV-1 infected cell line, which
was established from the cerebrospinal fluid of a HAM
patient, was examined.
[0079]
HCT-4 and HCT-5, which were HTLV-1 infected cell
lines established from the cerebrospinal fluid of HAM
patients, were donated from a professor, Tatsufumi
Nakamura of the Nagasaki International University. HCT-4
was cultured in R2MI1640 culture medium containing 10%
FBS (GIBCO), a 1% penicillin-streptomycin solution (Wako)
CA 03050221 2019-07-15
- 53 -
and 100 U/mL IL-2 (Cell Science & Technology Institute,
Inc.); whereas HCT-5 was cultured by using 10% FBS, 1%
penicillin-streptomycin solution, 1% L-glutamine (SIGMA)
and 200 U/mL IL-2. HCT-4 (3 x 106 cells) or HCT-5 (2.5 x
106 cells) were seeded in a culture medium (20 mL) in a
75 cm2-culture flask. DMSO was added and compound A or B
was added so as to provide a final concentration of 1 M
and culture was carried out at 37 C in 5% CO2 conditions
for 21 days while repeating subculture. In the
subculture, a culture solution containing HCT-4 treated
with DMSO so as to correspond to 3 x 106 cells, whereas a
culture solution containing HOT-5 treated with DMSO so as
to correspond to 2.5 x 106 cells were taken and each
added to a new culture medium to obtain a final volume of
20 mL, and then, further compound A or B was added so as
to obtain the same concentration as above. Day 7, 14 and
21 after initiation of culture, cells were recovered from
the culture solution and the density of the cells was
measured. In this manner, the effect of compound A or B
on cell proliferation was examined. The density of cells
was determined by seeding cultured cells in a 96-well
plate in a volume of 100 L per well, adding 10 L of
Cell counting kit-8 (CCK-8) (Dojindo Laboratories
laboratory) per well, incubating the cells at 37 C for 3
hours and measuring absorbance at 450 nm by a plate
reader (iMark Microplate Reader, Biorad). The
proliferation rates of cell groups treated with compound
CA 03050221 2019-07-15
- 54 -
A or compound B were each calculated based on the cell
group treated with DMSO as a control. The results were
as shown in Figure 6.
[0080]
As shown in Figure 6, both of compound A and B
successfully and significantly reduce the viability of
HTLV-1 infected cells (inducing HAM), which are derived
from the cerebrospinal fluid, compared to the group
treated with DMSO. From this, it was demonstrated that
compound A and B are effective for treating HAM.
[0081]
Next, in a 6-well plate, HCT-4 (4.5 x 105 cells) or
HCT-5 (3.75 x 105 cells) were seeded. A solution of
compound A or B prepared with DMSO was serially diluted
(4-fold dilution from 10000 nM was serially repeated 8
times) and added thereto. The cells were repeatedly
subcultured at intervals of 3 to 4 days in a culture
solution of 3 mL in total at 37 C in 5% CO2 condition for
14 days. In the subculture, a culture solution
containing HCT-4 in the Dms0-treated group were added to
a new culture medium such that the cell number was 4.5 x
105 cells, whereas a culture solution containing HCT-5 in
the DMSO-treated group such that the cell number was 3.75
x 105 cells, and then, further compound A or B was added
so as to obtain the same concentration as above to
prepare a culture solution of 3 mL in total. The cells
cultured for 14 days in individual conditions were
=
CA 03050221 2019-07-15
=
- 55 -
recovered and the density of the cells were measured. In
this manner, the effect of compound A or B on cell
proliferation was examined. The density of cells was
determined by seeding the cultured cells (100 L) per
well in a 96-well plate, adding 10 L of CCK-8 per well,
incubating the cells at 37 C for 3 hours and measuring
absorbance at 450 nm by a plate reader. The
proliferation rate of a group treated with compound A or
compound B was calculated based on the group treated with
DMSO as a control. The results were as shown in Figure 7.
[0082]
As shown in Figure 7, compound A and B successfully
reduced the viability of HTLV-1 infected cells
established from the cerebrospinal fluid of a HAM patient
in a concentration-dependent manner. GI50 of compound A
for HCT-4 cells was 7.63 nM and G150 of compound B for
HCT-4 cells was 5.92 nM; whereas, GI50 of compound A for
HCT-5 cells was 185.4 nM and GI50 of compound B for HCT-5
cells was 90.6 nM.
[0083]
Example 6: Activity of EZH1/2 dual inhibitor to induce
apoptosis of HAM infection cells
In this Example, experiments were carried out using
the cells cultured for 21 days in Example 5. To detect
apoptotic cells in the cells cultured for 21 days by
adding 1 M of compound A or compound B, the cells were
stained by use of PE Annexin V apoptosis Detection Kit I
CA 03050221 2019-07-15
,
- 56 -
(BD) and analyzed by FACS. In this analysis, the viable
cells were detected based on FSC (forward scatter)-SSC
(side scatter) plots. The viable cells were analyzed by
Annexin V-PE (annexin V) and 7-AAD (7-amino actinomycin
D). Early apoptotic cells were detected as Annexin V (+)
7-AAD (-) cells. The results were as shown in Figure 8
(HCT-4 cells) and Figure 9 (HCT-5 cells).
[0084]
As shown in Figure 8, it was apparent that the
number of viable cells decreases in HCT-4 cells treated
with compound A or B. Also in Figure 8, it was apparent
that the number of early apoptotic cells increased in
HCT-4 cells treated with compound A or B.
As shown in Figure 9, it was apparent that the
number of viable cells decreases in HCT-5 cells treated
with compound A or B. Also in Figure 9, it was apparent
that the number of early apoptotic cells increased in
HCT-5 cells treated with compound A or B.
